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Background: Atypical teratoid rhabdoid tumor (ATRT) patients display a dismal median overall survival of less than
1 year. A consistent fraction of cases carries de-novo SMARCB1/INI1 constitutional mutations in the setting of the
“rhabdoid tumor predisposition syndrome” and the outcome is worst in infant syndromic ATRT patients.
Case presentation: We here describe a patient affected by mosaic Klinefelter syndrome and by rhabdoid tumor
predisposition syndrome caused by constitutional SMARCB1/INI1 heterozygous mutation c.118C>T (Arg40X).
Patient’s ATRT primary tumor occurred at 2 years of age concurrent with metastatic lesions. The patient was
rendered without evidence of disease by combined surgery, high-dose poli-chemotherapy and craniospinal
irradiation, followed by autologous hematopoietic stem cell transplantation. At the onset of a spinal lesion 5.5 years
later, both tumors were pathologically and molecularly evaluated at the national central pathology review board
and defined as ATRT in a syndromic patient, with strong evidence of a clonal origin of the two lesions. The patient
was then treated according to SIOP guidelines and is now alive without evidence of disease 24 months after the
detection of metastatic disease and 90 months after the original diagnosis.
Conclusion: The report underscores the current utility of multiple comprehensive approaches for the correct
diagnosis and clinical management of patients affected by rare and atypical brain neoplasms. Successful local
control of disease and achievement of long-term survival is possible in ATRT patients even in the setting of
rhabdoid tumor predisposition syndrome, infant age at diagnosis and metastatic spread of disease, thus justifying
the efforts for the management of this severe condition.
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SMARCB1/INI1 is a highly conserved core subunit of
the SWI/SNF family of ATP-dependent chromatin re-
modeling complexes [1] and acts as a tumor suppressor
gene inactivated in malignant rhabdoid tumors (MRT)
of childhood, encompassing renal, soft-tissue and brain
cancers [2] and characterized by SMARCB1/INI1 genetic* Correspondence: pmodena@cro.it; maura.massimino@istitutotumori.mi.it
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reproduction in any medium, provided the orinactivation as a primary, recurrent event [3,4]. Notably, a
consistent fraction of cases carries de-novo SMARCB1/
INI1 constitutional mutations in the setting of the so
called “rhabdoid tumor predisposition syndrome” [5,6].
MRTs of the brain, known as Atypical Teratoid
Rhabdoid Tumor (ATRT), were initially considered as a
medulloblastoma subgroup with poor prognosis and have
been suggested as a separate entity since 1996 [7,8], but
only recently systematic SMARCB1/INI1 immunohisto-
chemistry and mutational screening in newly diagnosed
pediatric brain tumors [9-11] has allowed the definition of
the incidence, clinical, pathologic and molecular features
of ATRT [11]. ATRT represents an aggressive neoplasm ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2407/13/100childhood with a dismal prognosis, presenting a median
overall survival of less than 12 months and less than 20%
progression-free survival at 1 year from diagnosis. Particu-
larly, infant age [12,13], metastasis at diagnosis [12] and
the status of carrier of rhabdoid tumor predisposition syn-
drome [5,14,15] invariably lead ATRT patients to rapid le-
thal outcome, with less than 30% overall survival at 1 year.
To our knowledge, no long-term survival patient has been
reported so far presenting all these three adverse progno-
sis’ features.
Case presentation
Patient’s history and clinical features
The patient (Figure 1A), a 24 months-old boy affected
by mosaic Klinefelter syndrome (47, XXY [14]/46,XY
[65]) presented with cerebellar and endocranial hyper-
tension symptoms. Initial MRI examination showed a












Figure 1 A, Schematic representation of the family tree of index case
(wt= wild type; Arg40X denotes the constitutional mutation found in index
years (y). B, Brain MRI of primary ATRT lesion. C, MRI of metastatic lesion. D
tumor from index case, showing absence of SMARCB1/INI1 protein expressitri-ventricle hydrocephalon and transependimal liquoral
re-absorpion (Figure 1B). He was submitted to surgery
with the intent of complete tumor removal but post-
operative staging showed multiple hemispherical cere-
bellar nodules, concurrent spinal metastases at the
lumbar and caudal tracts, and cerebrospinal fluid dis-
semination. Final histological diagnosis, performed at
the original neuropathology unit, was medulloblastoma.
He was sent to our Unit for adjuvant treatment that,
according to the Italian Association of Hematology and
Oncology (AIEOP) protocol for high-risk infant medu-
lloblastoma [16,17] (Figure 2), consisted of sequential
high-dose (hd) methotrexate and vincristine, hd-etoposide,
hd-cycloposphamide and hd-carboplatin delivered with-
in a 2 month time without obtaining a satisfying
metastatic tumor response. Craniospinal irradiation
according to the hyperfractionated accelerated radio-
therapy schedule [16] was therefore delivered, with aC
iagnosis At relapse
E
. Karyotype and SMARCB1/INI1 molecular evaluation (E) is reported
case). Present age and age of onset of clinical symptoms is given in
, Hematoxylin eosin staining and E, SMARCB1/INI1 staining of ATRT
on in cancer cells.
Diagnosis,
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Figure 2 Schedules of chemotherapy and radiotherapy.
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posterior fossa up to a total dose of 59.7 Gy. Complete re-
sponse was eventually obtained and two subsequent con-
solidation courses with high-dose thiotepa were delivered
thereafter, followed by rescue autologous hemopoietic
stem cells that were harvested after hd-etoposide in the
pre-radiant phase.
The child was thereafter asymptomatic until November
2010 when he complained of gait disturbances and lower
back pain. The MRI performed showed an intrarachideal
spinal lesion extended from L3 to L5 (Figure 1C) that was
surgically excised sub-totally. The staging was repeated
with whole CNS MRI and cytological cerebrospinal fluid
examination and did not show other neoplastic sites. Ana-
lysis of this second tumor under central pathology review
board concluded for the diagnosis of ATRT, supported by
negative SMARCB1/INI1 staining. Central pathology re-
evaluation of primary tumor revealed negative SMARCB1/
INI1 staining, prompting a reassessment of the original
diagnosis to ATRT (Figure 1D-E). Parents accepted the
new treatment (Table 1), proposed based on International
Society of Pediatric Oncology (SIOP) guidelines for
rhabdoid tumors, consisting of chemotherapy alternating
adriamycin and vincristine, carboplatin plus etoposide and
ifosfamide (ICE regimen) and actinomycin D, cyclophos-
phamide and vincristine, leading to complete response ofspinal residual disease. Due to previous craniospinal ir-
radiation, no intratechal chemotherapy was planned. The
systemic treatment finally included one myeloablative
course with high-dose carboplatin and thiotepa. Following
restoration from aplastic period he was re-irradiated on
the spinal tumor bed. Radiation was delivered to the spine
and conus medullaris from L3 to S4 and reached a total
dose of 39.6 gray (Gy) with a standard fractionation of
1.8 Gy/day. The child is now 114 months old and is alive
without evidence of disease 24 months after spinal relapse
and 90 months after the original diagnosis.
The patient is at present in the full-course of the pri-
mary school and is assisted by a tutor. Indeed, the cogni-
tive and developmental status of the patient was
influenced by Klinefelter syndrome, whose symptoms
were not properly and early addressed due to cancer oc-
currence. During the course of the ATRT disease, the
patient suffered hydrocephalus at diagnosis and he was
affected by posterior fossa syndrome in the post-
operative period. He had a direct neuro-cognitive assess-
ment 2 years after the end of the first treatment and
displayed a full-scale IQ of 68, verbal IQ of 72 and per-
formance IQ of 72, but we lack basal evaluations. For all
these reasons, it is not possible to draw any conclusion
on the morbidity and cognitive/developmental impact of
specific therapies applied.
Table 1 Microsatellite alleles and sequence polimorphisms of mitochondrial DNA hypervariable regions (HV1 and HV2)
detected in constitutional DNA, primary tumor and metastasis of ATRT index case
Marker Costituzional DNA Primary tumor Metastatic tumor Mb position (chr22 start)
D22S427
(22q11.21) 97 - 97 97 97 18,591,317
D22S257
(22q11.23) 120 - 128 128 128 23,568,429
D22S1174
(22q11.23) 139 - 141 139 139 24,488,486
D22S1154
(22q12.1) 264 - 266 264 264 26,617,527
D22S1163
(22q12.1) 148 - 162 162 162 27,918,651
HV1 - 16183C 16183C -
16189C 16189C
HV2 - 263 G 263 G -
309.3C 309.3C
315.1C 315.1C
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Negative immunostaining for SMARCB1/INI1 protein
prompted us to further investigate SMARCB1/INI1 gene
status in Carnoy’s fixed (primary tumor) and formalin-
fixed (spinal metastasis), paraffin-embedded biopsies, in
order to corroborate the pathological results. SMARCB1/
INI1 exon amplification and sequencing revealed the
presence of a homozygous exon 2 c.118C>T (Arg40X)
mutation in both the primary and metastatic tumor le-
sions (Figure 3A).
Investigation of patient’s peripheral blood-derived
DNA revealed the presence of the same mutation in het-
erozygosity (Figure 3B), thus establishing the constitu-
tional origin of the mutation. Both parents and the
younger brother carried instead a wild-type sequence
(Figure 1C), suggesting the de-novo origin of the muta-
tion in the index case. The c.118C>T (Arg40X) mutation
has already been described in malignant rhabdoid tumor
[18] and leads to the creation of a premature stop codon
in SMARCB1/INI1 exon 2.
Loss of the second allele in tumor tissue as a second hit
for SMARCB1/INI1 inactivation was suggested by sequen-
cing results (Figure 3A) and further supported by multiplex
ligation-dependent probe amplification (MLPA) gene dosage
analysis that revealed hemizygous deletion of the entire
SMARCB1/INI1 gene and flanking chromosome 22q probes
in both tumors (Figure 3D-E). Normal DNAs and samples
carrying known SMARCB1/INI1 imbalances were used as
controls. The presence of SMARCB1/INI1 hemyzigous dele-
tion was confirmed also by Real-time quantitative PCR ana-
lysis of SMARCB1/INI1 copy number by means of relative
quantification using standard curve method (not shown).In order to study the relationship between the two
tumor lesions, they were further investigated by analyz-
ing the status of 22q microsatellite loci and mitochon-
drial DNA hypervariable regions. The results (Table 1)
indicate a complete identity of the two lesions and there-
fore support a clonal origin and strongly suggest that the
spinal tumor represents a metastatic spread of the pri-
mary tumor.Conclusions
Malignant rhabdoid tumors are lethal neoplasms of in-
fancy, which can affect renal and extrarenal locations,
including soft tissues and brain [19,20]. Notably, these
tumors also represent the sole manifestation of a herit-
able cancer predisposition syndrome caused by constitu-
tional alterations of SMARCB1/INI1 tumor suppressor
gene [5,6]. Overall survival in rhabdoid tumor patients is
dismal and survival is worst in the setting of infant pa-
tients and patients affected by rhabdoid tumor predis-
position syndrome [5]. In malignant rhabdoid tumors
affecting the brain (called Atypical Teratoid Rhabdoid
Tumors – ATRT), similar results are reported and
germline mutations are associated with fatal outcome
within two-years from diagnosis [14].
Outcome improvements in ATRT have been reported
with the adoption of high-dose, multimodality chemo-
therapy regimens [13,21-23]. Indeed, case reports of
long-term survival in ATRT have been described [24-26]
but, to our knowledge, no case reported so far carried
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Figure 3 (See legend on next page.)
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Figure 3 A-C, Electropherogram of normal and tumor DNA-derived sequences showing the presence of heterozygous exon 2 c.118C>T
(Arg40X) in (A) patient’s constitutional DNA and the same homozygous mutation (B) in tumor samples. C, Parental sample, displaying normal
DNA sequence. D-E, Fragment analysis (D) and histogram (E) of MLPA results for SMARCB1/INI1 gene dosage analysis in primary tumor tissue and
in control samples. Red dots indicate peaks corresponding to SMARCB1/INI1 fragments.
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http://www.biomedcentral.com/1471-2407/13/100We here describe a long-term surviving patient af-
fected by syndromic ATRT and who is alive 7.5 years
after the original diagnosis and 2 years after onset of a
spinal metastatic lesion. All the analyses performed
showed an identical genetic profile between the primary
and metastatic ATRT lesions. Although we cannot for-
mally exclude that the two lesions represent the occur-
rence of two independent primary ATRTs, our genetic
analyses as well as the clinical history of the patient,
characterized by the presence of metastatic spread since
the occurrence of the primary tumor, make this hypoth-
esis very unlikely and support a clonal origin of the two
lesions.
ATRT tumor from proband case displayed a biallelic
inactivation of SMARCB1/INI1 gene by heterozygous
loss of one allele and Arg40X mutation in the exon 2 of
the second allele. This mutation, by causing a premature
stop codon, is of obvious pathogenic consequence and
has already been reported in the spectrum of mutations
occurring in malignant rhabdoid tumors [18]. Although
to our knowledge this is the first report of Arg40X oc-
currence in a syndromic ATRT patient, such mutation
has been already reported in syndromic extracerebral
MRT and has functional consequences overlapping those
of other exon 2 mutations previously reported in syn-
dromic ATRT patients, such as Arg53X [5]. These data
indicate that Arg40X mutation can occur in both spor-
adic and syndromic, and in both cerebral and
extracerebral MRTs, thus suggesting that no specific
genotype-phenotype correlation exists.
The patient under study was affected by mosaicism for
Klinefelter syndrome, the most common human sex
chromosome disorder, presenting 18% of peripheral
blood lymphocytes with chromosome X aneuploidy and
this report represents, to our knowledge, the first associ-
ation of ATRT with Klinefelter. Despite individual case
reports emphasized the association between Klinefelter
and specific cancers’ risk, reviews of epidemiological
data do not support a generalized increased risk of can-
cer in Klinefelter patients [27,28], which remains signifi-
cant only for breast cancer if compared to the general
population of males but not of females [27]. In addition,
there is no evidence of recurrent X chromosome abnor-
malities or X-chromosome gene(s) mutation in ATRT
tumor samples analyzed by whole-genome approaches
[4,29], so we suggest that the occurrence of ATRT in
our patient is unrelated to Klinefelter syndrome. Fur-
thermore, in cancer patients Klinefelter is associatedwith increased risk of cancer mortality [27] and, al-
though the risk is variable in different cancer types,
Klinefelter did not display a protective effect in any indi-
vidual tumor type investigated. Therefore, we consider
very unlikely the possibility that the constitutional
karyotype of the patient may have positively affected the
course of ATRT, being responsible for the observed
long-term survival.
The patient presents cognitive and developmental
delay, as a consequence of Klinefelter syndrome as well
as ATRT treatment complications. In this complex sce-
nario, the lack of multiple neuropsychological assess-
ments during the different disease stages impedes to
draw any conclusion on the morbidity and cognitive/de-
velopmental impact of specific therapies applied.
To conclude, the observed successful local control of
disease and achievement of long-term survival in our
molecularly-proven ATRT patient even in the setting of
rhabdoid tumor predisposition syndrome justifies the
efforts to advance the management of this severe
condition.
Materials and methods
Exon PCR and sequencing
Mutational analysis was performed by exon amplifica-
tion and sequencing as previously described [30].
Primers and PCR conditions are available upon request.
PCR products were enzymatically purified with ExoSap
(Affymetrix) and sequenced with BigDye Terminator
chemistry (Applera). Sequencing products were run on
an ABI3130xl genetic analyzer (Applera) and electrophe-
rograms were visually inspected. The two strands of
mitochondrial DNA hypervariable regions HVS-I and
HVSII were amplified and sequenced following standard
procedures [31].
Multiplex ligation-dependent probe amplification
For Multiplex ligation-dependent probe amplification
(MLPA), tumor DNA (100 ng) was subjected to DNA
copy number analysis using MLPA kits P258-B1, (MRC-
Holland), following manufacturer instructions, together
with normal DNA samples and cancer cell line samples
with known SMARCB1/INI1 gene copy number alter-
ations as controls. Fragment separation was performed on
an ABI3130xl genetic analyzer (Applera). Raw data peak
pattern evaluation was performed using GeneMapper soft-
ware (Applera) and Coffalyser software was used for data
analysis (MRC-Holland). Normal DNAs were used as
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number alterations were used as controls for the sensitiv-
ity of the test.
Real-time quantitative PCR
Analysis of SMARCB1/INI1 copy number by real-time
quantitative PCR was performed by means of relative
quantification using standard curve method [32], using
TaqMan assays 4401631 (Applera) for RPPH1 endogen-
ous control gene and Hs01497967_cn (Applera) for
SMARCB1/INI1. Standard curve was constructed using
normal control DNA and 22q normal copy FFPE con-
trols served as calibrator.
Microsatellites
Microsatellite alleles’ analysis was performed by capillary
electrophoresis of fluoresceinated amplification products
obtained from peripheral blood- and tumor-derived
DNA. PCR products were run on an ABI3130xl genetic
analyzer (Applera) and raw data were acquired with
GeneMapper software and the peak pattern was visually
evaluated.
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